Royal Bank of Canada’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-505
| Closed | -$2K | – | 7904 |
|
|
2023
Q3 | $2K | Buy |
505
+371
| +277% | +$2.53K | ﹤0.01% | 6843 |
|
|
2023
Q2 | $0 | Buy |
134
+133
| +13,300% | +$395 | ﹤0.01% | 7912 |
|
|
2023
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 7711 |
|
|
2022
Q4 | $0 | Sell |
1
-6
| -86% | -$238 | ﹤0.01% | 8022 |
|
|
2022
Q3 | $0 | Buy |
+7
| New | +$320 | ﹤0.01% | 8102 |
|
|
2022
Q2 | – | Sell |
-114
| Closed | -$7K | – | 7968 |
|
|
2022
Q1 | $7K | Sell |
114
-220
| -66% | -$18.3K | ﹤0.01% | 7154 |
|
|
2021
Q4 | $40K | Buy |
334
+169
| +102% | +$28.5K | ﹤0.01% | 6503 |
|
|
2021
Q3 | $23K | Buy |
165
+61
| +59% | +$12.1K | ﹤0.01% | 6647 |
|
|
2021
Q2 | $29K | Buy |
104
+20
| +24% | +$5.05K | ﹤0.01% | 6375 |
|
|
2021
Q1 | $18K | Buy |
84
+30
| +56% | +$8.29K | ﹤0.01% | 6497 |
|
|
2020
Q4 | $13K | Buy |
54
+52
| +2,600% | +$6.43K | ﹤0.01% | 6278 |
|
|
2020
Q3 | $0 | Buy |
2
+1
| +100% | +$91 | ﹤0.01% | 7064 |
|
|
2020
Q2 | $0 | Sell |
1
-7
| -88% | -$613 | ﹤0.01% | 7023 |
|
|
2020
Q1 | $0 | Sell |
8
-59
| -88% | -$5.62K | ﹤0.01% | 7155 |
|
|
2019
Q4 | $5K | Buy |
67
+58
| +644% | +$6.49K | ﹤0.01% | 6378 |
|
|
2019
Q3 | $1K | Buy |
+9
| New | +$1.24K | ﹤0.01% | 6562 |
|
|
2019
Q1 | – | Sell |
-3
| Closed | -$1K | – | 7212 |
|
|
2018
Q4 | $1K | Sell |
3
-8
| -73% | -$1.61K | ﹤0.01% | 6633 |
|
|
2018
Q3 | $3K | Buy |
11
+10
| +1,000% | +$2.62K | ﹤0.01% | 6456 |
|
|
2018
Q2 | $0 | Buy |
+1
| New | +$292 | ﹤0.01% | 6866 |
|
Other funds holding EVLO
Royal Bank of Canada's EVLO Position: Q4 2023 in Review
Royal Bank of Canada sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2023, closing a stake of 505 shares — an estimated $2K sold.
Royal Bank of Canada first reported a position in EVLO in Q2 2018 and held it in 19 quarters. The position peaked at $40K in Q4 2021. 2 funds tracked by Wall St. Rank hold EVLO as of Q4 2023.
- Royal Bank of Canada reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- Royal Bank of Canada sold 505 Evelo Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $2K.
- Royal Bank of Canada first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 19 quarters.
- Royal Bank of Canada's Evelo Biosciences, Inc. Common Stock position peaked at $40K in Q4 2021.
- 2 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2023.
Based on Royal Bank of Canada's 13F filing for Q4 2023, filed 14 Feb 2024.